The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumors

The introduction of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematological diseases, particularly in combating blood cancer. The success of this cell therapy approach has led to the development of approximately seven commercial CAR-T based drugs. However, th...

Full description

Saved in:
Bibliographic Details
Main Authors: M. R. Khaliulin, R. N. Safin, M. A. Kunst, E. R. Bulatov
Format: Article
Language:Russian
Published: ABV-press 2024-04-01
Series:Успехи молекулярной онкологии
Subjects:
Online Access:https://umo.abvpress.ru/jour/article/view/647
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849241198442577920
author M. R. Khaliulin
R. N. Safin
M. A. Kunst
E. R. Bulatov
author_facet M. R. Khaliulin
R. N. Safin
M. A. Kunst
E. R. Bulatov
author_sort M. R. Khaliulin
collection DOAJ
description The introduction of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematological diseases, particularly in combating blood cancer. The success of this cell therapy approach has led to the development of approximately seven commercial CAR-T based drugs. However, the application of CAR-T therapy for solid tumors has proven to be less effective due to challenges such as the varied antigens in solid tumors, an immunosuppressive tumor environment, limited immune cell infiltration, reduced CAR-T cell activity and toxicity issues. To solve these problems, scientists are making efforts to improve and improve the methods of treatment of solid tumors. Chemotherapy is the standard treatment for a large number of malignant neoplasms. It is also used before starting cell therapy for lymphodepletion and better engraftment of injected CAR-T cells. It has been shown that chemotherapy can reduce the immunosuppressive effect of the tumor microenvironment, destroy the stroma, and promote better infiltration of the tumor by CAR-T cells, improving their survival, persistence, cytotoxicity, and influencing the metabolism of immune cells inside the tumor. The effectiveness of combining chemotherapy and CAR-T cell therapy relies on various factors such as tumor type, dosage, treatment schedule, CAR-T cell composition, and individual biological traits. Similarly, radiation therapy can enhance tumor cell vulnerability to specific treatments while also supporting tumor cell survival.In this review, we discuss the use of CAR-T therapy to combat solid tumors, regarding the challenges of treating solid tumors, ways to overcome them, and also touch upon the possibility of using combination treatments to improve the effectiveness of cell therapy.
format Article
id doaj-art-cc8bd4f30ea84290a83347e23cc1a447
institution Kabale University
issn 2313-805X
2413-3787
language Russian
publishDate 2024-04-01
publisher ABV-press
record_format Article
series Успехи молекулярной онкологии
spelling doaj-art-cc8bd4f30ea84290a83347e23cc1a4472025-08-20T04:00:14ZrusABV-pressУспехи молекулярной онкологии2313-805X2413-37872024-04-01111314510.17650/2313-805X-2024-11-1-31-45316The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumorsM. R. Khaliulin0R. N. Safin1M. A. Kunst2E. R. Bulatov3Kazan (Volga Region) Federal UniversityRepublican Clinical Oncology Dispensary named after Prof. M.Z. Sigal RussiaRepublican Clinical Hospital of the Ministry of Health of the Republic of TatarstanKazan (Volga Region) Federal University; Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of SciencesThe introduction of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematological diseases, particularly in combating blood cancer. The success of this cell therapy approach has led to the development of approximately seven commercial CAR-T based drugs. However, the application of CAR-T therapy for solid tumors has proven to be less effective due to challenges such as the varied antigens in solid tumors, an immunosuppressive tumor environment, limited immune cell infiltration, reduced CAR-T cell activity and toxicity issues. To solve these problems, scientists are making efforts to improve and improve the methods of treatment of solid tumors. Chemotherapy is the standard treatment for a large number of malignant neoplasms. It is also used before starting cell therapy for lymphodepletion and better engraftment of injected CAR-T cells. It has been shown that chemotherapy can reduce the immunosuppressive effect of the tumor microenvironment, destroy the stroma, and promote better infiltration of the tumor by CAR-T cells, improving their survival, persistence, cytotoxicity, and influencing the metabolism of immune cells inside the tumor. The effectiveness of combining chemotherapy and CAR-T cell therapy relies on various factors such as tumor type, dosage, treatment schedule, CAR-T cell composition, and individual biological traits. Similarly, radiation therapy can enhance tumor cell vulnerability to specific treatments while also supporting tumor cell survival.In this review, we discuss the use of CAR-T therapy to combat solid tumors, regarding the challenges of treating solid tumors, ways to overcome them, and also touch upon the possibility of using combination treatments to improve the effectiveness of cell therapy.https://umo.abvpress.ru/jour/article/view/647adoptive cell therapychimeric antigen receptorcar-t cellchemotherapysolid tumors
spellingShingle M. R. Khaliulin
R. N. Safin
M. A. Kunst
E. R. Bulatov
The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumors
Успехи молекулярной онкологии
adoptive cell therapy
chimeric antigen receptor
car-t cell
chemotherapy
solid tumors
title The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumors
title_full The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumors
title_fullStr The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumors
title_full_unstemmed The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumors
title_short The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumors
title_sort use of t cells with chimeric antigen receptor car t in combination with chemotherapy and radiotherapy for the treatment of solid tumors
topic adoptive cell therapy
chimeric antigen receptor
car-t cell
chemotherapy
solid tumors
url https://umo.abvpress.ru/jour/article/view/647
work_keys_str_mv AT mrkhaliulin theuseoftcellswithchimericantigenreceptorcartincombinationwithchemotherapyandradiotherapyforthetreatmentofsolidtumors
AT rnsafin theuseoftcellswithchimericantigenreceptorcartincombinationwithchemotherapyandradiotherapyforthetreatmentofsolidtumors
AT makunst theuseoftcellswithchimericantigenreceptorcartincombinationwithchemotherapyandradiotherapyforthetreatmentofsolidtumors
AT erbulatov theuseoftcellswithchimericantigenreceptorcartincombinationwithchemotherapyandradiotherapyforthetreatmentofsolidtumors
AT mrkhaliulin useoftcellswithchimericantigenreceptorcartincombinationwithchemotherapyandradiotherapyforthetreatmentofsolidtumors
AT rnsafin useoftcellswithchimericantigenreceptorcartincombinationwithchemotherapyandradiotherapyforthetreatmentofsolidtumors
AT makunst useoftcellswithchimericantigenreceptorcartincombinationwithchemotherapyandradiotherapyforthetreatmentofsolidtumors
AT erbulatov useoftcellswithchimericantigenreceptorcartincombinationwithchemotherapyandradiotherapyforthetreatmentofsolidtumors